Efficacy of Beraprost in Lowering Pulmonary Arterial Pressure in Children

Pediatric Pulmonary Hypertension Clinical Trial

Official title: Efficacy of Beraprost in Lowering Pulmonary Arterial Pressure in Pulmonary Arterial Hypertension Children Associated With Left to Right Shunt Congenital Heart Defect

Status Completed

Clinical Trial Summary

To analyze the efficacy of beraprost and sildenafil for treatment of pulmonary hypertension in children with left to right shunt.

analyze the efficacy and side effects.

Clinical Trial Description

Eligibility criteria:

Inclusion:

1. children aged 1-17 years with left to right shunt, diagnosed as pulmonary hypertension.

2. free from chronic pulmonary disease

3. never performed any cardiac surgical

4. never got any treatment for PH

5. agree to enroll in this study. Exclusion

1. suffer from portal hypertension, HIV and connective tissue disease 2. under interferon therapy.

Outcome measure:

Pulmonary artery pressure ;

Related Conditions & MeSH terms

• Hypertension
• Hypertension, Pulmonary
• Pediatric Pulmonary Hypertension

• NCT number: NCT03431649
• Study type: Interventional
• Source: Dr. Soetomo General Hospital
• Status: Completed
• Phase: Phase 4
• Start date: April 1, 2017
• Completion date: October 30, 2017